CannaPharmaRX, Inc.

CPMD

US13765D1090

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 02:38:59 2024-06-11 pm EDT			5-day change	1st Jan Change
0.0146 ^USD	-5.81%		+10.61%	+758.82%

Jun. 04	CannaPharmaRX, Inc. Executes Multi-Year Supply Agreement with ICAN Green S.A. de C.V to Create Distribution Network in the Latin Americas	CI
Jun. 04	CannaPharmaRX, Inc. Receives First Purchase Order	CI

CannaPharmaRX, Inc. Announces Unaudited Consolidated Earnings Results for the Nine Months Ended September 30, 2018

January 07, 2019 at 05:27 pm EST

CannaPharmaRX, Inc. announced unaudited consolidated earnings results for the nine months ended September 30, 2018. For the period, the company reported loss from operations of $320,617. Net loss was $2,073,024 and basic and diluted loss per share was $0.11.

Latest news about CannaPharmaRX, Inc.

CannaPharmaRX, Inc. Executes Multi-Year Supply Agreement with ICAN Green S.A. de C.V to Create Distribution Network in the Latin Americas	Jun. 04	CI
CannaPharmaRX, Inc. Receives First Purchase Order	Jun. 04	CI
CannaPharmaRX, Inc. Announces CEO Changes	Jun. 04	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	May. 16	CI
CannaPharmaRX, Inc. Receives First Purchase Order and Begins Shipment of Product	Mar. 14	CI
CannaPharmaRX, Inc. Executes Multi-Year Supply Agreement with Ican to Create Distribution Network in the Latin Americas	Mar. 05	CI
CannaPharmaRx, Inc Enters into Strategic Supply Agreement with Cantek Holdings	Feb. 16	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
CannaPharmaRX, Inc. Announces Executive Changes	23-10-13	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-10-13	CI
CannaPharmaRX, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-09-22	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-09-01	CI
CannaPharmaRx Expands Board of Directors	23-08-25	CI
CannaPharmaRX, Inc. Announces CEO Changes	23-06-23	CI
CannaPharmaRX, Inc. Signs Supply Agreement with Y.S.A Holdings for Up to $15 Million Annually of Commercial Cannabis	23-03-30	CI
CannaPharmaRX, Inc. completed the acquisition of LTB Management LLC.	23-03-20	CI
CannaPharmaRX, Inc. agreed to acquire LTB Management LLC.	23-02-20	CI
CannaPharmaRx Receives Canada Revenue Agency License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million Expected	23-01-11	CI
CannaPharmaRx, Inc Receives Cultivation License from Health Canada and Projects 2023 Revenue over $30 Million	22-12-21	CI
CannaPharmaRX, Inc. Provides Revenue Guidance for the Full Year 2023	22-12-21	CI
CannaPharmaRx, Inc. Receives Cultivation License from Health Canada	22-12-21	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-21	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-22	CI
CannaPharmaRX, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI

Chart CannaPharmaRX, Inc.

Duration

Period

More charts

Company Profile

CannaPharmaRx, Inc. is focused on the acquisition and development of state-of-the-art cannabis growing facilities in Canada. The Company is engaged in producing customizable medical cannabis and craft products. Its business strategy is to produce a high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. The Company is focused on operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis. The Company also offers a range of services to assist with cannabis inventory management.

Sector

Pharmaceuticals

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CANNAPHARMARX, INC.	+758.82%	10.14M
ELI LILLY AND COMPANY	+48.53%	779B
NOVO NORDISK A/S	+40.67%	631B
JOHNSON & JOHNSON	-6.37%	354B
MERCK & CO., INC.	+20.93%	333B
ABBVIE INC.	+8.21%	301B
ASTRAZENECA PLC	+16.75%	249B
ROCHE HOLDING AG	-1.19%	216B
NOVARTIS AG	+10.85%	214B
AMGEN INC.	+4.40%	163B

Other Pharmaceuticals